Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | PTGS2 | P35354 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.38 |
| ▸ | TSHR | P16473 | 2/20 | 0.38 |
| ▸ | HPGD | P15428 | 2/20 | 0.38 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.38 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.38 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 0.38 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.37 |
| ▸ | CYP2D6 | P10635 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 2/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA2 | P00918 | 2/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.35 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Phosphine SCHEMBL28191605 | 0.87 | PTGS2 (0.44) | PTGS2ALDH1A1KDM4ETSHRHPGD | |
| SCHEMBL12401834 | 0.82 | MAP3K14 (0.41) | PTGS2ALDH1A1TSHRHPGDL3MBTL1 | |
| SCHEMBL12401805 | 0.82 | LMNA (0.41) | PTGS2ALDH1A1KDM4ETSHRHPGD | |
| SCHEMBL6673577 | 0.82 | PTGS2 (0.41) | PTGS2ALDH1A1TSHRHPGDTDP1 | |
| SCHEMBL25950818 | 0.80 | PTGS2 (0.40) | KMT2APTGS2ALDH1A1KDM4ETSHR | |
| SCHEMBL5083897 | 0.80 | ERBB2 (0.45) | PTGS2ALDH1A1TSHRHPGDHSD17B10 | |
| SCHEMBL54507 | 0.79 | KMT2A (0.47) | KMT2AALDH1A1KDM4ETSHRHPGD | |
| SCHEMBL24008338 | 0.77 | DRD2 (0.48) | PTGS2ALDH1A1KDM4ETSHRTDP1 | |
| SCHEMBL2125454 | 0.77 | PTGS2 (0.35) | PTGS2ALDH1A1KDM4ETSHRHPGD | |
| SCHEMBL25950827 | 0.77 | ALDH1A1 (0.37) | KMT2APTGS2ALDH1A1KDM4ETSHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-31 | — | — | US | disclosed |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | IP2IPO INNOVATIONS LIMITED (GB) | 2023-08-10 | — | — | US | disclosed |
| US-9139536-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-09-22 | — | — | US | disclosed |
| US-9095590-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-08-04 | — | — | US | disclosed |
| US-8986740-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2015-03-24 | — | — | US | disclosed |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC (US) | 2014-10-02 | — | — | US | disclosed |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | ABBVIE INC. (US) | 2014-08-21 | — | — | US | disclosed |
| EP-2222646-B1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBVIE BAHAMAS LTD (BS) | 2014-01-22 | — | — | EP | disclosed |
| EP-2639226-A1 | Anti-infective pyrimidines and uses thereof | ABBOTT LABORATORIES (US) | 2013-09-18 | — | — | EP | disclosed |
| US-8501238-B2 | Anti-infective agents and uses thereof | ABBVIE INC. (US) | 2013-08-06 | — | — | US | disclosed |
| EP-2203430-B1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | ABBOTT LAB (US) | 2011-06-15 | — | — | EP | disclosed |
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | ABBOTT LABORATORIES (US) | 2011-03-24 | — | — | US | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-23 | — | — | US | disclosed |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-07-09 | — | — | US | disclosed |
| WO-2009039135-A1 | N-PHENYL-DIOXO-HYDROPYRIMIDINES USEFUL AS HEPATITIS C VIRUS (HCV) INHIBITORS | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039134-A1 | ANTI-INFECTIVE PYRIMIDINES AND USES THEREOF | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
| WO-2009039127-A1 | URACIL OR THYMINE DERIVATIVE FOR TREATING HEPATITIS C | ABBOTT LABORATORIES (US) | 2009-03-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110070193-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | KMT2A 4704/4885PTGS2 1919/4885ALDH1A1 2117/4885 |
| US-20230271939-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | KMT2A 3150/4885PTGS2 196/4885ALDH1A1 2504/4885 |
| US-20230250082-A1 | 4-ETHYNYLPYRIDINE DERIVATIVES USEFUL AS GCN2 INHIBITORS | EIF2AK4, GCN1, EIF5B | KMT2A 3150/4885PTGS2 196/4885ALDH1A1 2504/4885 |
| US-20090176784-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | KMT2A 4704/4885PTGS2 1919/4885ALDH1A1 2117/4885 |
| US-20140294766-A1 | Anti-Infective Agents and Uses Thereof | MPO, SERPINB1, ELANE | KMT2A 4704/4885PTGS2 1919/4885ALDH1A1 2117/4885 |
| US-20140235638-A1 | Anti-Infective Agents and Uses Thereof | MPO, ELANE, LPO | KMT2A 4715/4885PTGS2 2301/4885ALDH1A1 2039/4885 |
| US-20090186912-A1 | ANTI-INFECTIVE AGENTS AND USES THEREOF | MPO, SERPINB1, ELANE | KMT2A 4704/4885PTGS2 1919/4885ALDH1A1 2117/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.